Who is sponsoring NCT00410540?

NCT00410540 is sponsored by Alza Corporation, DE, USA.

What condition does NCT00410540 study?

NCT00410540 studies Pain, Analgesics, Opioid.

What drugs are being tested in NCT00410540?

Interventions: OROS hydromorphone HCL ; Morphine sulfate.

What is the status of NCT00410540?

NCT00410540 is currently COMPLETED.

Last reviewed 2010-04-26 · How we verify

A Randomized, Double-Blind, Controlled Trial of Hydromorphone (Immediate and Sustained- Release) vs Morphine (Immediate and Sustained-release) in Cancer Pain

NCT00410540 Phase 3 COMPLETED

The purpose of this study was to demonstrate the clinical equivalence of hydromorphone and morphine (immediate-release \[IR\] and sustained-release \[SR\] formulations) using the "worst pain in the past 24 hours" item of the Brief Pain Inventory (BPI). The secondary objective of this study was to compare hydromorphone and morphine in the following variables: other pain measures, various questionnaires, and safety and tolerability variables.

Details

Lead sponsor	Alza Corporation, DE, USA
Phase	Phase 3
Status	COMPLETED
Enrolment	202
Completion	2001-05

Conditions

Pain
Analgesics, Opioid

Interventions

OROS hydromorphone HCL ; Morphine sulfate

Primary outcomes

The primary efficacy : Patient's assessment of "worst pain in the past 24 hours" Brief Pain Inventory (BPI) questions, scored daily in the patient's diary.